June 26, 2017 / 11:45 AM / 5 months ago

BRIEF-Enanta Pharmaceuticals announces new data on EDP-938

June 26 (Reuters) - Enanta Pharmaceuticals Inc

* Enanta Pharmaceuticals Inc - Announces new data on EDP-938

* Phase 1 clinical study for RSV expected to begin in fourth calendar quarter of 2017

* Lead compound shows greater than 4-log reduction in viral load in an animal model challenged with RSV Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below